These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 18483367)

  • 41. Epidermal growth factor receptor signaling in adenocarcinomas with bronchioloalveolar components.
    Sarkaria IS; Zakowski MF; Pham D; Hezel M; Ebright MI; Chuai S; Venkatraman ES; Kris MG; Rusch VW; Singh B
    Ann Thorac Surg; 2008 Jan; 85(1):216-23. PubMed ID: 18154814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
    Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
    Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.
    Yamashita H; Murakami N; Asari T; Okuma K; Ohtomo K; Nakagawa K
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1165-72. PubMed ID: 19101092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
    Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
    Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma.
    Lee EY; Cibull ML; Strodel WE; Haley JV
    Arch Pathol Lab Med; 1994 Mar; 118(3):235-9. PubMed ID: 7907854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
    Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
    Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder.
    Shafizadeh N; Grenert JP; Sahai V; Kakar S
    Hum Pathol; 2010 Apr; 41(4):485-92. PubMed ID: 20040392
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer.
    Tsutsui S; Kataoka A; Ohno S; Murakami S; Kinoshita J; Hachitanda Y
    Clin Cancer Res; 2002 Nov; 8(11):3454-60. PubMed ID: 12429634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
    Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
    Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastric carcinoma: expression of c-erbB-2/neu oncoprotein, epidermal growth factor receptor, cathepsin D, progesterone receptor and tumor associated glycoprotein-72 in different histological types.
    Peláez Buján Mdel C; Ruibal Morell A; Aza González J
    Rev Esp Enferm Dig; 1999 Dec; 91(12):826-37. PubMed ID: 10619912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
    Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis.
    Slesak B; Harlozinska A; Porebska I; Bojarowski T; Lapinska J; Rzeszutko M; Wojnar A
    Anticancer Res; 1998; 18(4A):2727-32. PubMed ID: 9703936
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases.
    Wei Q; Sheng L; Shui Y; Hu Q; Nordgren H; Carlsson J
    Ann Surg Oncol; 2008 Apr; 15(4):1193-201. PubMed ID: 18172732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Local expression of insulin-like growth factor-I, insulin-like growth factor-I receptor, and estrogen receptor alpha in ovarian cancer.
    An Y; Cai L; Wang Y; Zhu D; Guan Y; Zheng J
    Onkologie; 2009 Nov; 32(11):638-44. PubMed ID: 19887867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.
    Economou MA; All-Ericsson C; Bykov V; Girnita L; Bartolazzi A; Larsson O; Seregard S
    Acta Ophthalmol; 2008 Nov; 86 Thesis 4():20-5. PubMed ID: 19032678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biological markers and prognosis in recurrent oral cancer after salvage surgery.
    Agra IM; Carvalho AL; Pinto CA; Martins EP; Filho JG; Soares FA; Kowalski LP
    Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):743-9. PubMed ID: 18645125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases.
    Sato O; Wada T; Kawai A; Yamaguchi U; Makimoto A; Kokai Y; Yamashita T; Chuman H; Beppu Y; Tani Y; Hasegawa T
    Cancer; 2005 May; 103(9):1881-90. PubMed ID: 15772959
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.